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E-mail: robert.porter@porthosp.nhs.ukFaecal microbiota transplantation (FMT) is an effective treat-
ment for recurrent Clostridium difﬁcile infection (CDI), with an
initial cure rate of 81% after the ﬁrst FMT, rising to 94% after
two FMTs [1]. However, for the small number of subjects
whose infection fails to respond to this approach, there are no
clearly deﬁned therapeutic options.
In our hospital, a consultation was requested regarding a 74-
year-old man with underlying B cell chronic lymphocytic
leukaemia who had presented with recurrent CDI. He had pre-
viously completed four cycles of chemotherapy, but he fell, with a
resulting subdural haematoma, and his chemotherapy was
stopped. He developed diarrhoea in August 2013, and his stool
was glutamate dehydrogenase (GDH) positive (Alere, USA) and
toxin A/B enzyme-linked immunosorbent assay positive (Alere,
USA). He was treated with a ten-day course of oral metronida-
zole 400mg three times a day. This was subsequently followed by
a further course when symptoms returned. When he again
developed diarrhoea, he underwent colonoscopy, which
conﬁrmed pseudomembranous colitis. At this point, he was
treatedwith oral vancomycin 125mg four times a day for 14 days.
When this failed, he was treated with a pulsed/tapered 6-week
course of vancomycin. During treatment, his symptoms were
suppressed, but when he received alternate-day vancomycin, his
symptoms returned, and laboratory testing conﬁrmed toxin-
positive C. difﬁcile. He was subsequently maintained on oral
vancomycin 125 mg three or four times a day. In late November
2013, he received his ﬁrst FMT (unrelated donor 100 g of faeces
in 500 mL of 0.9% saline passed by nasojejunal tube), but afterClinical Microbiology and Infection © 2014 European Society of Cinitial symptom control, he experienced relapse after nearly 3
weeks. He received a second FMT in January 2014 from a
different donor (unrelated donor 120 g of faeces in 500 mL of
0.9% saline passed by nasojejunal tube). Symptoms returned 2
weeks later. A stool specimen tested at this time conﬁrmedGDH
and toxin A/B positivity.
During interval periods, the subject was maintained on oral
vancomycin, which controlled his symptoms. If vancomycin was
withdrawn, the subject experienced symptomatic relapse, and
he tested positive for CDI by GDH/toxin on ﬁve separate oc-
casions. Ribotyping was only performed on one isolate from
May 2014 (ribotype 078). No analysis of donor/recipient
microbiota before or after transplantation was performed,
which may have yielded insight into why initial FMT had failed.
At this point, several options were offered to the subject: (a)
lifelong vancomycin maintenance therapy, (b) teicoplanin pulse/
tapered 6-week course followed by rifaximin, (c) ﬁdaxomicin or
(d) pulse/tapered FMTs. It was explained that all options had
little or no evidence base for success in this setting.
The subject was extremely keen to be cured and had tolerated
the FMTs well. After discussion with his family, he opted for
further FMTs.
In June 2014 he was treated with one FMT a week for 3
weeks, then a 2-week break, followed by a fourth FMT in week
6. All FMTs were performed with different unrelated faecal
donors, which were made up in 500 mL of 0.9% saline with at
least 50 g of donor faeces. All FMTs were performed via a
nasojejunal tube, which was left in situ for the ﬁrst three FMTs,
then removed and a new tube inserted for the fourth FMT.
Vancomycin maintenance therapy was stopped the night
before the ﬁrst FMT. The subject has now been free of symptoms
for over 4months, and his bowel habits have returned to normal.
It is possible that the vancomycin received in May, between
the last positive toxin test and pulsed FMT, could have itself
resulted in a deﬁnitive cure. However, this seems unlikely, as
standard pharmacotherapy had failed in the preceding 9
months. The subject received no other antibiotics or proton
pump inhibitors during his period of infection, and he mostly
resided in his own home, with short admissions to our hospital,
which had no known CDI outbreaks.
CDI is associated with a high mortality and morbidity [2],
and recurrent disease occurs in approximately 22% of subjects
[3]. Current interest in FMT for recurrent CDI is based on its
good outcomes, apparent safety [1] and cost-effectiveness [4].
However, options for those whose disease does not respond to
therapy have not been well discussed in the literature to date.
Maintaining subjects on oral vancomycin may suppress symp-
toms, but it costs £4576 for an annual course of 125 mg four
times a day and increases the risk of vancomycin resistance inClin Microbiol Infect 2015; 21: e23–e24
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base and may be tried as an alternative in cases of vancomycin
failure. Fidaxomicin has some evidence from subgroup analysis
for recurrent CDI, and it may be a useful option in subjects with
underlying malignancy. However, after multiple recurrences, it
may be less effective [5].
In this case, it was hypothesized that FMT may fail in subjects
who are reinfected from their environment or from residual
spores in their gut, and that a single FMT may not be robust
enough to prevent this in certain hosts. By repeating FMTs the
gut ﬂora would be bolstered at the point where C. difﬁcile may
regain a foothold.
Although FMT failure is infrequent, when it does occur,
pulsed FMT may be a safe, relatively cheap and effective option.Transparency declarationThe author reports no conﬂicts of interest relevant to this
letter.Clinical Microbiology and Infection © 2014 European Society of Clinical Microbiology and InfectReferences[1] Van Nood E, Vrieze A, Nieuwdorp M, Fuentes S, Zoetendal EG, de
Vos WM, et al. Duodenal infusion of donor feces for recurrent Clos-
tridium difﬁcile. N Engl J Med 2013;368:407–15.
[2] Hensgens MPM, Goorhuis A, Dekkers OM, van Benthem BHB,
Kuijper EJ. All-cause and disease-speciﬁc mortality in hospitalized pa-
tients with Clostridium difﬁcile infection: a multicenter cohort study. Clin
Infect Dis 2013;56:1108–16.
[3] Vardakas KZ, Polyzos KA, Patouni K, Rafailidis PI, Samonis G,
Falagas ME. Treatment failure and recurrence of Clostridium difﬁcile
infection following treatment with vancomycin or metronidazole: a
systematic review of the evidence. Int J Antimicrob Agents 2012;40:
1–8.
[4] Konijeti GG, Sauk J, Shrime MG, Gupta M, Ananthakrishnan AN. Cost-
effectiveness of competing strategies for management of recurrent
Clostridium difﬁcile infection: a decision analysis. Clin Infect Dis 2014;58:
1507–14.
[5] Orenstein R. Fidaxomicin failures in recurrent Clostridium difﬁcile
infection: a problem of timing. Clin Infect Dis 2012;55:613–4.ious Diseases. Published by Elsevier Ltd. All rights reserved, CMI, 21 e23–e24
